Neuland Laboratories Q1 FY27 Earnings Call — Analysis (NSE: NEULANDLAB)
Neuland Q1FY27 revenue up 16.3% YoY to ₹650 Cr with 35.5% EBITDA margin; peptide commercial module commissioning next month with confirmed project pipeline.
Result quality: strong — Margin expansion. Management sentiment: optimistic.
The take
Q1FY27 Total Income ₹650.1 Cr ( +16.3% YoY ) . New guidance — FY27 development revenue go up . New story: Peptide inflection .
Results
Total income ₹650.1 Cr, +16.3% YoY; EBITDA ₹231.1 Cr (margin 35.5%); PAT ₹147.4 Cr vs ₹13.7 Cr YoY; gross margin 61.2% vs 55.3% YoY.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Total Income | ₹650.1 Cr | +16.3% | yoy · Q1FY27 |
| EBITDA | ₹231.1 Cr | point_in_time · Q1FY27 | |
| EBITDA Margin | 35.5% | point_in_time · Q1FY27 | |
| Profit After Tax | ₹147.4 Cr | +vs ₹13.7 Cr in Q1FY26 | yoy · Q1FY27 · Q1FY26: ₹13.7 Cr |
| Gross Margin | 61.2% | +vs 55.3% in Q1FY26 | yoy · Q1FY27 · Q1FY26: 55.3% |
| Working Capital Days | 84 days | −from 137 days at FY26 end | sequential · Q1FY27 · FY26: 137 days |
| Capex Outflow (Q1FY27) | ₹121.6 Cr | point_in_time · Q1FY27 | |
| Capex Approved in Quarter | ₹203 Cr | point_in_time · Q1FY27 · ₹196 Cr for Unit 1 expansion | |
| Total Approved Capex (13 quarters) | ₹1,460 Cr | point_in_time · cumulative · over last 13 quarters | |
| Total Capex Spent | ₹870 Cr | point_in_time · cumulative |
Guidance
Management aspirational for ~20% revenue growth in FY27 and FY28; peptide facility commissioning September 2026; one more CMS commercialization expected in FY27, 1-2 in FY28.
What management committed to
- We aspire to grow [total revenue] at about 20% in FY27 and FY28. — about 20%, FY27 and FY28
- We expect to have one more commercialization in FY27 and probably 1 or maybe even 2 in FY28. — one more this year, 1 or 2 next year, FY27 and FY28
- [The peptide manufacturing plant Module 1] will be commissioned next month (September 2026) and manufacturing qualification will be done by then. — commissioned next month, manufacturing qualification done, Q2FY27
- We have a couple of projects which are going to use [the new peptide facility]. — a couple of projects
- Development revenue will go up in FY27 compared to FY26. — go up, FY27
- Long-term EBITDA margin target is 25% plus. — 25% plus, long-term
Key themes
Peptide inflection and strategic partnership-led growth
How the narrative shifted
- Peptide inflection: Peptide capabilities built over 15 years are now gaining external validation with commercial module commissioning and project pipeline, positioning Neuland in a high-moat modality.
- CMS commercial concentration vs pipeline diversification: Current CMS growth relies on ~3 molecules, but the development pipeline is strengthening and should add new commercializations from FY27, broadening the base.
- Strategic partnership and account-based model: Management is shifting from project-based transactions to becoming a platform partner for innovator companies, exemplified by the Gland Pharma collaboration.
- Capex upcycle and capacity expansion: The company is investing at a meaningfully higher pace, with Unit 1 expansion and future plans for newer modalities and geographic diversification, potentially involving M&A.
- Inherent quarterly lumpiness: Management repeatedly warns that CDMO business is inherently uneven, Q4 was inflated by spillovers, and investors should take a multi-quarter view rather than extrapolate single quarters.
- Supply chain diversification tailwind: Geopolitical and macroeconomic dynamics are driving supply chain diversification, creating strategic opportunities for integrated CDMO partners like Neuland.
Operational commentary
- Peptide manufacturing Module 1 to be commissioned in September 2026; already has at least two projects lined up for the facility, customer interest accelerating.
- Strategic collaboration with Gland Pharma for sterile API manufacturing, focusing on niche generics; asset-light partnership leveraging Gland's aseptic capabilities and Neuland's complex API synthesis.
- Two new development-stage projects added in Q1FY27, including peptide projects, both advanced clinical stage; potential for significant future commercial volumes.
- CMS commercial revenue still concentrated among ~3 molecules, but pipeline set to add 1 new commercialization in FY27 and 1-2 in FY28, improving diversification.
- Board approved ₹196 Cr capacity expansion at Unit 1, part of a broader accelerated capex cycle; management hints at future investments in newer modalities and geographic diversification.
- Working capital days sharply reduced to 84 days from 137 days at FY26-end, reflecting inventory optimization and cash conversion focus.
- GDS portfolio performing well with key contributors Ezetimibe, Mirtazapine, Escitalopram, Aripiprazole; expanding into Brazil, Japan, South Korea, Turkey, and pursuing lifecycle management with innovators.
- Management shifting from project-based to account-based relationships, aiming to become a platform partner for large pharma innovators.
Analyst Q&A
Q. What kind of growth should we expect for full year FY27, and any risk from destocking?
We've always aspired to grow at about 20% for FY27 & FY28, but we are cautious not to give exact guidance. No destocking risk seen for now; order visibility is consistent.
Q. Can you provide more color on peptide Module 1 utilization and potential commercial project this year?
Plant commissioning next month with manufacturing qualification ready. Multiple projects at various stages, but did not commit to a commercial project this year.
Q. Is CMS commercial growth concentrated in a few large programs or becoming more diversified?
Growth is driven by about 3 molecules from commercial CMS. They are not one-offs but there will be lumpiness. Pipeline adding new commercializations soon.
Q. How should we think about monetization of the strategic customer conversations and platform approach?
Confidence is high; today's visible opportunities are far larger (₹500-1000 Cr/year vs ₹50 Cr five years ago). This is guiding our capex ambition and bolder moves.
Q. Is this the beginning of a structurally higher earning phase, and should margin expansion sustain?
Trend line is positive, but quarterly unevenness will remain. Long-term EBITDA target 25%+, anything above is a bonus. ROCE may dip with capex.
Q. Will the company consider a stock split or bonus issue?
It's a Board matter; we will take the suggestion and discuss it in our Board and look at all elements.
Research and educational content only. Not investment advice.